JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB108407

Anti-Cullin 3/CUL-3 antibody [EPR3195]

4

(1 Review)

|

(12 Publications)

Rabbit Recombinant Monoclonal Cullin 3/CUL-3 antibody. Suitable for WB and reacts with Mouse, Rat, Human samples. Cited in 12 publications.

View Alternative Names

KIAA0617, CUL3, Cullin-3, CUL-3

2 Images
Western blot - Anti-Cullin 3/CUL-3 antibody [EPR3195] (AB108407)
  • WB

Unknown

Western blot - Anti-Cullin 3/CUL-3 antibody [EPR3195] (AB108407)

All lanes:

Western blot - Anti-Cullin 3/CUL-3 antibody [EPR3195] (ab108407) at 1/5000 dilution

Lane 1:

HeLa cell lysate at 10 µg

Lane 2:

SH-SY5Y cell lysate at 10 µg

Lane 3:

PC12 cell lysate at 10 µg

Lane 4:

NIH 3T3 cell lysate at 10 µg

Predicted band size: 89 kDa

false

Western blot - Anti-Cullin 3/CUL-3 antibody [EPR3195] (AB108407)
  • WB

CiteAb

Western blot - Anti-Cullin 3/CUL-3 antibody [EPR3195] (AB108407)

Cullin 3/CUL-3 western blot using anti-Cullin 3/CUL-3 antibody [EPR3195] ab108407. Publication image and figure legend from Cristini, A., Park, J. H., et al., 2016, Nucleic Acids Res, PubMed 26578593.

ab108407 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab108407 please see the product overview.

The production of DSBs depends on Top1 degradation in CPT-treated quiescent cells. (A–C) Serum-starved WI38 hTERT cells were co-transfected with siRNAs against cullin 3 and cullin 4B or against a control sequence and then treated with DMSO (-CPT) or 25 μM CPT (+CPT) for 1 h. (A and B) Western blot of the indicated proteins. αTubulin : loading control. (C) Number of γH2AX foci per nucleus from one representative experiment (246–348 nuclei were analyzed for each treatment) out of three. ***p < 0.001. (D and E) Serum-starved WI38 hTERT cells were treated with DMSO or MG132 (50 μM) for 1 h before exposure to 0.8 Gy IR. One hour post-irradiation, cells were co-stained for γH2AX (green) and 53BP1 (red). (D) Representative pictures. (E) Number of γH2AX foci per nucleus from one representative experiment (162–180 nuclei were analyzed for each treatment) out of three. Ns : not significant. (F and G) U2OS EV28 cells were treated with DMSO or MG132 (10 μM) for 1 h before the addition of ethanol (untreated) or 300 nM 4-hydroxitamoxifen (4OHT) for 4 h to express AsiSI in the nucleus (42). (F) Representative pictures of cells co-stained for γH2AX (green) and 53BP1 (red). (G) ChIP analysis using an anti-γH2AX antibody (black) or a non-immune antibody (IgG, gray). Enrichment was assessed by QPCR amplification using primers proximal to two AsiSI sites located inside two genes (Gene I : SFRS6, Gene II : CCD47) and primers distal to an AsiSI site (Control). Enrichment was normalized to the maximum recovery for each experiment (means ± SEM, n = 3). Ns : not significant; *p < 0.05. In the microscopic images, nuclear contours, identified by DAPI staining (not shown), are indicated by dashed lines. Bars : 10 μm.

false

  • Carrier free

    Anti-Cullin 3/CUL-3 antibody [EPR3195] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR3195

Isotype

IgG

Carrier free

No

Reacts with

Mouse, Rat, Human

Applications

WB

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/5000", "WB-species-notes": "<p></p>", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>" }, "Mouse": { "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/5000", "WB-species-notes": "<p></p>", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>" }, "Rat": { "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/5000", "WB-species-notes": "<p></p>", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>" } } }

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Storage information
Stable for 12 months at -20°C

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Core component of multiple cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complexes which mediate the ubiquitination and subsequent proteasomal degradation of target proteins. BCR complexes and ARIH1 collaborate in tandem to mediate ubiquitination of target proteins (PubMed : 27565346). As a scaffold protein may contribute to catalysis through positioning of the substrate and the ubiquitin-conjugating enzyme. The E3 ubiquitin-protein ligase activity of the complex is dependent on the neddylation of the cullin subunit and is inhibited by the association of the deneddylated cullin subunit with TIP120A/CAND1. The functional specificity of the BCR complex depends on the BTB domain-containing protein as the substrate recognition component. BCR(KLHL42) is involved in ubiquitination of KATNA1. BCR(SPOP) is involved in ubiquitination of BMI1/PCGF4, BRMS1, MACROH2A1 and DAXX, GLI2 and GLI3. Can also form a cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex containing homodimeric SPOPL or the heterodimer formed by SPOP and SPOPL; these complexes have lower ubiquitin ligase activity. BCR(KLHL9-KLHL13) controls the dynamic behavior of AURKB on mitotic chromosomes and thereby coordinates faithful mitotic progression and completion of cytokinesis. BCR(KLHL12) is involved in ER-Golgi transport by regulating the size of COPII coats, thereby playing a key role in collagen export, which is required for embryonic stem (ES) cells division : BCR(KLHL12) acts by mediating monoubiquitination of SEC31 (SEC31A or SEC31B) (PubMed : 22358839, PubMed : 27716508). BCR(KLHL3) acts as a regulator of ion transport in the distal nephron; by mediating ubiquitination of WNK4 (PubMed : 23387299, PubMed : 23453970, PubMed : 23576762). The BCR(KLHL20) E3 ubiquitin ligase complex is involved in interferon response and anterograde Golgi to endosome transport : it mediates both ubiquitination leading to degradation and 'Lys-33'-linked ubiquitination (PubMed : 20389280, PubMed : 21670212, PubMed : 21840486, PubMed : 24768539). The BCR(KLHL21) E3 ubiquitin ligase complex regulates localization of the chromosomal passenger complex (CPC) from chromosomes to the spindle midzone in anaphase and mediates the ubiquitination of AURKB (PubMed : 19995937). The BCR(KLHL22) ubiquitin ligase complex mediates monoubiquitination of PLK1, leading to PLK1 dissociation from phosphoreceptor proteins and subsequent removal from kinetochores, allowing silencing of the spindle assembly checkpoint (SAC) and chromosome segregation (PubMed : 23455478). The BCR(KLHL22) ubiquitin ligase complex is also responsible for the amino acid-stimulated 'Lys-48' polyubiquitination and proteasomal degradation of DEPDC5. Through the degradation of DEPDC5, releases the GATOR1 complex-mediated inhibition of the TORC1 pathway (PubMed : 29769719). The BCR(KLHL25) ubiquitin ligase complex is involved in translational homeostasis by mediating ubiquitination and subsequent degradation of hypophosphorylated EIF4EBP1 (4E-BP1) (PubMed : 22578813). The BCR(KLHL25) ubiquitin ligase complex is also involved in lipid synthesis by mediating ubiquitination and degradation of ACLY (PubMed : 27664236). The BCR(KBTBD8) complex acts by mediating monoubiquitination of NOLC1 and TCOF1, leading to remodel the translational program of differentiating cells in favor of neural crest specification (PubMed : 26399832). Involved in ubiquitination of cyclin E and of cyclin D1 (in vitro) thus involved in regulation of G1/S transition. Involved in the ubiquitination of KEAP1, ENC1 and KLHL41 (PubMed : 15983046). In concert with ATF2 and RBX1, promotes degradation of KAT5 thereby attenuating its ability to acetylate and activate ATM. The BCR(KCTD17) E3 ubiquitin ligase complex mediates ubiquitination and degradation of TCHP, a down-regulator of cilium assembly, thereby inducing ciliogenesis (PubMed : 25270598). The BCR(KLHL24) E3 ubiquitin ligase complex mediates ubiquitination of KRT14, controls KRT14 levels during keratinocytes differentiation, and is essential for skin integrity (PubMed : 27798626). The BCR(KLHL18) E3 ubiquitin ligase complex mediates the ubiquitination of AURKA leading to its activation at the centrosome which is required for initiating mitotic entry (PubMed : 23213400). The BCR(KEAP1) E3 ubiquitin ligase complex acts as a key sensor of oxidative and electrophilic stress by mediating ubiquitination and degradation of NFE2L2/NRF2, a transcription factor regulating expression of many cytoprotective genes (PubMed : 15601839, PubMed : 16006525). As part of the CUL3(KBTBD6/7) E3 ubiquitin ligase complex functions mediates 'Lys-48' ubiquitination and proteasomal degradation of TIAM1 (PubMed : 25684205). By controlling the ubiquitination of that RAC1 guanine exchange factors (GEF), regulates RAC1 signal transduction and downstream biological processes including the organization of the cytoskeleton, cell migration and cell proliferation (PubMed : 25684205). The BCR(KBTBD4) E3 ubiquitin ligase complex targets CoREST corepressor complex components RCOR1, KDM1A/LSD1 and HDAC2 for proteasomal degradation with RCOR1 likely to be the primary target while degradation of KDM1A and HDAC2 is likely due to their association with RCOR1 (PubMed : 33417871). It also targets RCOR3, MIER2 and MIER3 for proteasomal degradation as well as associated proteins ZNF217 and RREB1 with degradation being dependent on the presence of an ELM2 domain in the target proteins (PubMed : 36997086). The BCR(ARMC5) complex mediates premature transcription termination of transcripts that are unfavorably configured for transcriptional elongation by mediating ubiquitination of Pol II subunit POLR2A (PubMed : 35687106, PubMed : 38225631, PubMed : 39504960, PubMed : 39667934). Required for 'Lys-63'-linked ubiquitination of large ribosomal subunit protein MRPL12 (PubMed : 37526061). Protects against human enterovirus D68 infection by mediating the ubiquitination and subsequent degradation of viral protein VP1 (PubMed : 40396757).
See full target information CUL3

Publications (12)

Recent publications for all applications. Explore the full list and refine your search

Clinical and experimental medicine 25:243 PubMed40640517

2025

SPOP-dependent destabilization of SYT12 in a GSK-3β-dependent manner in papillary thyroid cancer cells.

Applications

Unspecified application

Species

Unspecified reactive species

Shaocheng Zhou,Qidan Du,Limei Xu,Xiaohong Kang

Acta pharmaceutica Sinica. B 14:729-750 PubMed38322326

2024

Trilogy of drug repurposing for developing cancer and chemotherapy-induced heart failure co-therapy agent.

Applications

Unspecified application

Species

Unspecified reactive species

Xin Chen,Xianggang Mu,Lele Ding,Xi Wang,Fei Mao,Jinlian Wei,Qian Liu,Yixiang Xu,Shuaishuai Ni,Lijun Jia,Jian Li

The Journal of general virology 103: PubMed36301238

2022

Vaccinia virus BTB-Kelch proteins C2 and F3 inhibit NF-κB activation.

Applications

Unspecified application

Species

Unspecified reactive species

Rui-Yao Zhang,Mitchell A Pallett,Jamie French,Hongwei Ren,Geoffrey L Smith

Cancer research and treatment 54:525-540 PubMed34237211

2021

A Hypoxia-Induced SCFFBXL1 E3 Ligase Ubiquitinates and Degrades the MEN1 Tumor Suppressor to Promote Colorectal Cancer Tumorigenesis.

Applications

Unspecified application

Species

Unspecified reactive species

Jun Zeng,Xiao-Qing Xiao,Zhi-Yong Zhou

Bioengineered 12:2459-2468 PubMed34227919

2021

Pyrroloquinoline quinone (PQQ) alleviated sepsis-induced acute liver injury, inflammation, oxidative stress and cell apoptosis by downregulating CUL3 expression.

Applications

Unspecified application

Species

Unspecified reactive species

Yanhong Wu,Meiling Zhao,Zhaoheng Lin

PloS one 15:e0234708 PubMed32555680

2020

PD173074 blocks G1/S transition via CUL3-mediated ubiquitin protease in HepG2 and Hep3B cells.

Applications

Unspecified application

Species

Unspecified reactive species

Chuchu Qiao,Hongyan Qian,Jue Wang,Tingting Zhao,Pengyu Ma,Sicen Wang,Tao Zhang,Xinshe Liu

Journal of virology 93: PubMed30814284

2019

Vaccinia Virus BBK E3 Ligase Adaptor A55 Targets Importin-Dependent NF-κB Activation and Inhibits CD8 T-Cell Memory.

Applications

Unspecified application

Species

Unspecified reactive species

Mitchell A Pallett,Hongwei Ren,Rui-Yao Zhang,Simon R Scutts,Laura Gonzalez,Zihan Zhu,Carlos Maluquer de Motes,Geoffrey L Smith

Journal of cellular physiology 234:19977-19989 PubMed30945295

2019

Inflammation-dependent downregulation of miR-194-5p contributes to human intervertebral disc degeneration by targeting CUL4A and CUL4B.

Applications

Unspecified application

Species

Unspecified reactive species

Zhi Chen,Yingchao Han,Chao Deng,Wei Chen,Linyu Jin,Hao Chen,Kun Wang,Hongxing Shen,Lie Qian

Molecular medicine reports 16:7056-7063 PubMed28901482

2017

Detection of RACK1 and CTNNBL1‑induced activation of mouse splenocytes using an immunoprecipitation‑based technique.

Applications

Unspecified application

Species

Unspecified reactive species

Bohan Dong,Guangli Dai,Lei Xu,Damin Shi

Nucleic acids research 44:1161-78 PubMed26578593

2015

DNA-PK triggers histone ubiquitination and signaling in response to DNA double-strand breaks produced during the repair of transcription-blocking topoisomerase I lesions.

Applications

WB

Species

Human

Agnese Cristini,Joon-Hyung Park,Giovanni Capranico,Gaëlle Legube,Gilles Favre,Olivier Sordet
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com